Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Congrats ospreyeye
$KBIO @ 16.00 - we alerted in the 0.90's - Insane % Gains - Congrats!! -
Shorters paradise at these levels
KBIO insane afterhours. Hope you played it from $5.00 to $15.00 Who knows where it will be tomorrow.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118600803
lma0
ANSWER: BECAUSE YOUR NOT IN IT
YOU CALLED IT MAN
YOU IN ANY?
KBIO: Just churning here.Next leg up coming soon...Lol...
Lmao. You ain't kidding. Whichever way she goes tomorrow, it's gonna be full of excitement for sure!
Lol.Best T-Trades i've-seen-in-my-life.Prolly some IHUB group...Lol
Called the 'HUGE STUPID-ass SHORT' effect! Lolzzz
keep in mind
dont get greedy
heres why
http://ih.advfn.com/p.php?pid=nmona&article=69314353
Who I'm feeling really bad for right now are the ones who sold for pennies in the Friday AH session. Damn I should have grabbed some .45's when they were siting there in front of me Monday morning. :(
need to see that order to believe that
Message in reply to:
In for 8000 shares @ 16.65. Let's ride!
Lol no one can predict this no credits pls..
Insider is da winna..and some well ..back to trade tripz
OMG your gonna try to take credit for this
amazing
Congratulations everyone. I missed out. I hope some of you get new rolexes from selling your shares to shorts that need to cover at 14+ this is nuts . I woke up late on Monday and decided to stay out, had I put my 5k in like I planned under a dollar it would be worth over 100k. good job anyone who had the iron balls to buy this and hold.
In for 8000 shares @ 16.65. Let's ride!
$KBIO @ 16.00 - we alerted in the 0.90's - Insane % Gains - Congrats!! -
November 16, 2015 at 12:03 pm #10633
Ospreyeye
$KBIO 15 min. Chart – posted an alert and 15 min chart when the middle Bollinger Band resistance level broke – it was up 10% @ the time – share price doubled after the alert – be sure to checkout the chat for the best real time information –
You aint kidding. Unfortunately, tons of people are. Unreal.
$KBIO
NO WAY THIS STOCK IS GOING TO STAY UP AT THESE LEVELS
I WISH I COULD BORROW SHARES
KBIO glad I am not short. This traded at .18 Friday A/H. Unreal move
cant short either ...maybe for the best
Martin makin some $$$$$
Martin Shkreli Buys 1,211,115 Of Kalobios Pharmaceuticals @$1.35/Share -Form 4
KBIO
KBIO is not available for short selling at this time. For further assistance, please contact your branch. Scottrade
Martin Shkreli Buys 1,211,115 Of Kalobios Pharmaceuticals @$1.35/Share -Form 4
*KaloBios Shares Trading Up 330% Following Huge ~1.2M Share Purchase by Martin Shkrel
$11.60+++ @4:55
$10'S SHORT SQUEEZEEEE FEEL BAD FOR SHORTY WHO WENT TO DINNER AND HAS TO COME BACK TO THIS
KBIO
ya have any idea why ?
thank in advance
I only see a form 4
9.20'S GOING OFF
KBIO
THIS WAS THE MONST VOLUME AND GAIN I SEEN IN A WHILE FOR A POST MARKET GAINER. UNBELIEVABLE. MORE NEWS BETTER FOLLOW. I CANT SEE THIS MUCH GAIN JUST FROM DIRECTOR PURCHASING SHARES AT LOW PRICE
YEA THAT IS THE ONLY NEWS I SEE. NOTHING OF BUYOUT..
WHERE DO YOU SEE NEWS OF BUYOUT??
martin S buys 1.2+ million shares $$$$$$$$
KBIO-nice!
Dollar
$17+ buyout $$$$$$$$ myop
$7.15 @ 4:30PM!!!!!!!!!!! STILL MOVING
WTFFFFFFFFFFFFFFFFFFFFFFFFFFFF LOL STILL GOING
The DIRECTOR BOUGHT SHARES! NOW STOCK PRICE IN THE $3 RANGE LOL. THIS STOCK IS CRAZY. WHATS GOING ON WITH THE COMPANY
This going to drop like snow in north pole , good call on taking profit!!
* * $KBIO Video Chart 11-17-15 * *
Link to Video - click here to watch the technical chart video
yeah,,mcur,aqxp,,nxt up myop,apri also
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43312
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |